Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 18 de 18
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Arch Pharm Res ; 43(7): 744-754, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32715385

RESUMEN

Ganoderic Acid A (GA) has many pharmacological effects such as anti-tumor, antibacterial, anti-inflammatory, and immunosuppressive effects. However, the protective effect of GA on liver injury has not been reported. This study aimed to investigate the action of GA on insufficient methionine and choline combined with high-fat diet (HFD)-induced non-alcoholic fatty liver disease (NAFLD) in rats. NAFLD model was established by insufficient methionine and choline combined with high fat feeding to rats. The levels of Acetyl-CoA carboxylase, fatty acid synthase, sterol regulatory element binding protein, liver X receptors, AMP-activated protein kinase, peroxisome proliferator-activated receptor α, PPARg coactivator 1α and NF-κB pathway in the liver were detected by western blot. The results of this study demonstrated that the expression of GA can not only significantly decrease the live weight and liver weight per body weight of HFD mice, but also restore the alanine aminotransferase, aspartate aminotransferase, total bilirubin levels, triglyceride and cholesterol in serum. In addition, the expression of GA increased the levels of high-density lipoprotein cholesterol in serum, ameliorated pathological changes and decreased NAS score of mice's liver. In conclusion, the treatment with GA could improve NAFLD in rats by regulating the levels of signaling events involved in free fatty acid production, lipid oxidation and liver inflammation.


Asunto(s)
Ácidos Heptanoicos/farmacología , Inflamación/tratamiento farmacológico , Lanosterol/análogos & derivados , Metabolismo de los Lípidos/efectos de los fármacos , Enfermedad del Hígado Graso no Alcohólico/tratamiento farmacológico , Sustancias Protectoras/farmacología , Administración Oral , Animales , Citocinas/antagonistas & inhibidores , Citocinas/sangre , Citocinas/metabolismo , Dieta Alta en Grasa/efectos adversos , Ácidos Heptanoicos/administración & dosificación , Inflamación/inducido químicamente , Inflamación/metabolismo , Lanosterol/administración & dosificación , Lanosterol/farmacología , Masculino , Enfermedad del Hígado Graso no Alcohólico/inducido químicamente , Enfermedad del Hígado Graso no Alcohólico/metabolismo , Sustancias Protectoras/administración & dosificación , Ratas , Ratas Sprague-Dawley
2.
Int J Mol Sci ; 21(3)2020 Feb 05.
Artículo en Inglés | MEDLINE | ID: mdl-32033321

RESUMEN

We designed an intravitreal injection formulation containing lanosterol nanoparticles (LAN-NPs) via the bead mill method and evaluated the therapeutic effect of LAN-NPs on lens structure collapse and opacification using two rat cataract models (SCR-N, rats with slight lens structure collapse; SCR-C, rats with the combination of a remarkable lens structure collapse and opacification). The particle size of lanosterol in the LAN-NPs was around 50-400 nm. A single injection of LAN-NPs (0.5%) supplied lanosterol into the lens for 48 h, and no irritation or muddiness was observed following repeated injections of LAN-NPs for 6 weeks (once every 2 days). Moreover, LAN-NPs repaired the slight collapse of the lens structure in SCR-N. Although the remarkable changes in the lens structure of SCR-C were not repaired by LAN-NP, the onset of opacification was delayed. In addition, the increase of cataract-related factors (Ca2+ contents, nitric oxide levels, lipid peroxidation and calpain activity levels) in the lenses of SCR-C was attenuated by the repeated injection of LAN-NPs. It is possible that a deficiency of lanosterol promotes the production of oxidative stress. In conclusion, it is difficult to improve serious structural collapse with posterior movement of the lens nucleus with a supplement of lanosterol via LAN-NPs. However, the intravitreal injection of LAN-NPs was found to repair the space and structural collapse in the early stages in the lenses.


Asunto(s)
Catarata/prevención & control , Lanosterol/uso terapéutico , Cristalino/patología , Nanopartículas/uso terapéutico , Animales , Catarata/tratamiento farmacológico , Línea Celular , Humanos , Inyecciones Intravítreas , Lanosterol/administración & dosificación , Masculino , Nanopartículas/administración & dosificación , Óxido Nítrico/metabolismo , Estrés Oxidativo/efectos de los fármacos , Ratas , Ratas Transgénicas , Trastornos de la Visión/prevención & control
3.
Acta Pharmacol Sin ; 41(6): 782-790, 2020 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-31911637

RESUMEN

Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common life-threatening monogenetic diseases characterized by progressive enlargement of fluid-filled renal cysts. Our previous study has shown that Ganoderma triterpenes (GT) retards PKD renal cyst development. In the present study we identified the effective ingredient of GT in suppression of kidney cyst development. Using an in vitro MDCK cystogenesis model, we identified ganoderic acid A (GA-A) as the most promising candidate among the 12 ganoderic acid (GA) monomers. We further showed that GA-A (6.25-100 µM) significantly inhibited cyst growth in MDCK cyst model and embryonic kidney cyst model in vitro, and the inhibitory effect was reversible. In kidney-specific Pkd1 knockout (kPKD) mice displaying severe cystic kidney disease, administration of GA-A (50 mg· kg-1 ·d-1, sc) significantly attenuated renal cyst development. In both MDCK cells and kidney of kPKD mice, we revealed that GA-A dose-dependently downregulated the Ras/MAPK signaling pathway. The expression of proliferating cell nuclear antigen (PCNA) was also suppressed, suggesting a possible effect of GA-A on cell proliferation. These experimental data suggest that GA-A may be the main ingredient of GT as a potential therapeutic reagent for treating ADPKD.


Asunto(s)
Ganoderma/química , Ácidos Heptanoicos/farmacología , Lanosterol/análogos & derivados , Enfermedades Renales Poliquísticas/tratamiento farmacológico , Animales , Proliferación Celular/efectos de los fármacos , Células Cultivadas , Modelos Animales de Enfermedad , Perros , Relación Dosis-Respuesta a Droga , Ácidos Heptanoicos/administración & dosificación , Ácidos Heptanoicos/aislamiento & purificación , Inyecciones Subcutáneas , Lanosterol/administración & dosificación , Lanosterol/aislamiento & purificación , Lanosterol/farmacología , Células de Riñón Canino Madin Darby/efectos de los fármacos , Ratones , Ratones Endogámicos C57BL , Ratones Endogámicos ICR , Enfermedades Renales Poliquísticas/patología
4.
BMC Complement Altern Med ; 18(1): 265, 2018 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-30285704

RESUMEN

BACKGROUND: A substantial literature supports antidiabetic properties of the lanosteryl triterpene (methyl-3ß-hydroxylanosta-9,24-dien-21-oate, RA-3) isolated from Protorhus longifolia stem bark. However, the molecular mechanism(s) associated with the antihyperglycemic properties of the triterpene remained to be explored. The current study aimed at investigating the molecular mechanism(s) through which RA-3 improves insulin signaling in streptozotocin-induced type 1 diabetic rats. METHODS: The type 1 diabetic rats were treated daily with a single oral dose of RA-3 (100 mg/kg) for 28 days. The rats were then sacrificed, and blood, skeletal muscle and pancreases were collected for biochemical, protein expression and histological analysis, respectively. RESULTS: Persistently high blood glucose levels in the diabetic control rats significantly increased expression of IRS-1Ser307 while the expression of p-Akt Ser473, p-GSK-3ß Ser9, GLUT 4 and GLUT 2 were decreased. However, enhanced muscle insulin sensitivity, which was indicated by a decrease in the expression of IRS-1ser307 with a concomitant increase in the p-AktSer473, p-GSK-3ß Ser9, GLUT 4 and GLUT 2 expression were observed in the diabetic rats treated with RA-3. The triterpene-treated animals also showed an improved pancreatic ß-cells morphology, along with increased C-peptide levels. An increase in the levels of serum antioxidants such as catalase, superoxide dismutase, and reduced glutathione was noted in the rats treated with the triterpene, while their serum levels of interleukin-6 and malondialdehyde were reduced. CONCLUSIONS: It is apparent that RA-3 is able to improve the insulin signaling in type 1 diabetic rats. Its beta (ß)-cells protecting mechanism could be attributed to its ability to alleviate inflammation and oxidative stress in the cells.


Asunto(s)
Anacardiaceae/química , Diabetes Mellitus Tipo 1/tratamiento farmacológico , Hipoglucemiantes/administración & dosificación , Insulina/metabolismo , Lanosterol/análogos & derivados , Extractos Vegetales/administración & dosificación , Animales , Glucemia/metabolismo , Catalasa/metabolismo , Diabetes Mellitus Tipo 1/genética , Diabetes Mellitus Tipo 1/metabolismo , Transportador de Glucosa de Tipo 4/genética , Transportador de Glucosa de Tipo 4/metabolismo , Glutatión/metabolismo , Glucógeno Sintasa Quinasa 3 beta/genética , Glucógeno Sintasa Quinasa 3 beta/metabolismo , Humanos , Lanosterol/administración & dosificación , Masculino , Estrés Oxidativo/efectos de los fármacos , Corteza de la Planta/química , Ratas , Ratas Sprague-Dawley , Transducción de Señal , Superóxido Dismutasa/metabolismo
5.
Int J Mol Sci ; 17(11)2016 Oct 27.
Artículo en Inglés | MEDLINE | ID: mdl-27801787

RESUMEN

Ganoderma lucidum, a species of the Basidiomycetes class, has been attracting international attention owing to its wide variety of biological activities and great potential as an ingredient in skin care cosmetics including "skin-whitening" products. However, there is little information available on its inhibitory effect against tyrosinase activity. Therefore, the objectives of this study were to investigate the chemical composition of G. lucidum and its inhibitory effects on melanogenesis. We isolated the active compound from G. lucidum using ethanol extraction and ethyl acetate fractionation. In addition, we assayed its inhibitory effects on tyrosinase activity and melanin biosynthesis in B16F10 melanoma cells. In this study, we identified a bioactive compound, ganodermanondiol, which inhibits the activity and expression of cellular tyrosinase and the expression of tyrosinase-related protein-1 (TRP-1), TRP-2, and microphthalmia-associated transcription factor (MITF), thereby decreasing melanin production. Furthermore, ganodermanondiol also affected the mitogen-activated protein kinase (MAPK) cascade and cyclic adenosine monophosphate (cAMP)-dependent signaling pathway, which are involved in the melanogenesis of B16F10 melanoma cells. The finding that ganodermanondiol from G. lucidum exerts an inhibitory effect on tyrosinase will contribute to the use of this mushroom in the preparation of skin care products in the future.


Asunto(s)
Lanosterol/análogos & derivados , Melaninas/biosíntesis , Melanoma Experimental/tratamiento farmacológico , Reishi/química , Animales , Línea Celular Tumoral , Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Humanos , Interferón Tipo I/biosíntesis , Interferón Tipo I/genética , Lanosterol/administración & dosificación , Lanosterol/química , Melanocitos/efectos de los fármacos , Melanocitos/metabolismo , Melanoma Experimental/metabolismo , Melanoma Experimental/patología , Ratones , Factor de Transcripción Asociado a Microftalmía/biosíntesis , Factor de Transcripción Asociado a Microftalmía/genética , Monofenol Monooxigenasa/antagonistas & inhibidores , Fosforilación , Plantas Medicinales/química , Proteínas Gestacionales/biosíntesis , Proteínas Gestacionales/genética
6.
Molecules ; 21(10)2016 Oct 20.
Artículo en Inglés | MEDLINE | ID: mdl-27775633

RESUMEN

Triterpene acids (TAs) are the major bioactive constituents in the medicinal fungus Ganoderma lingzhi. However, fermentative production of TAs has not been optimized for commercial use, and whether the TAs isolated from G. lingzhi submerged culture mycelia possess antitumor activity needs to be further proven. In this study, enhanced TA yield and productivity were attained with G. lingzhi using response surface methodology. The interactions of three variables were studied using a Box-Benhnken design, namely initial pH, dissolved oxygen (DO) and fermentation temperature. The optimum conditions were an initial pH of 5.9, 20.0% DO and 28.6 °C. These conditions resulted in a TA yield of 308.1 mg/L in a 5-L stirred bioreactor. Furthermore, the optimized conditions were then successfully scaled up to a production scale of 200 L, and maximum TA production and productivity of 295.3 mg/L and 49.2 mg/L/day were achieved, which represented 80.9% and 111.5% increases, respectively, compared with the non-optimized conditions. Additionally, the triterpene acid extract (TAE) from G. lingzhi mycelia was found to be cytotoxic to the SMMC-7721 and SW620 cell lines in vitro, and the TAE exhibited dose-dependent antitumor activity against the solid tumor sarcoma 180 in vivo. Chemical analysis revealed that the key active triterpene compounds, ganoderic acid T and ganoderic acid Me, predominated in the extract.


Asunto(s)
Antineoplásicos/administración & dosificación , Reactores Biológicos/microbiología , Ganoderma/crecimiento & desarrollo , Sarcoma 180/tratamiento farmacológico , Triterpenos/administración & dosificación , Triterpenos/metabolismo , Animales , Antineoplásicos/química , Antineoplásicos/metabolismo , Antineoplásicos/farmacología , Línea Celular Tumoral , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Fermentación , Ganoderma/química , Humanos , Lanosterol/administración & dosificación , Lanosterol/análogos & derivados , Lanosterol/metabolismo , Lanosterol/farmacología , Ratones , Micelio/química , Micelio/crecimiento & desarrollo , Triterpenos/química , Triterpenos/farmacología , Ensayos Antitumor por Modelo de Xenoinjerto
8.
Theriogenology ; 85(4): 575-84, 2016 Mar 01.
Artículo en Inglés | MEDLINE | ID: mdl-26494176

RESUMEN

Lanosterol is a precursor of meiosis-activating sterols in the cholesterol biosynthetic pathway and induces a physiological signal that instructs the oocyte to reinitiate meiosis. In this study, we examined the effect of lanosterol on IVM of porcine oocytes, specifically on nuclear maturation, cytoplasmic maturation by investigating intracellular glutathione (GSH) levels and lipid content, embryonic development after parthenogenetic activation and somatic cell nuclear transfer (SCNT), and on gene expression in cumulus cells, oocytes, and SCNT-derived blastocysts. There was no significant difference in nuclear maturation rates between the control and treatment groups (10, 50, and 100 µM of lanosterol added to IVM culture medium). Supplementation with 50-µM lanosterol significantly increased lipid content and GSH levels and decreased reactive oxygen species levels compared with the control. In addition, oocytes treated with 50 µM of lanosterol exhibited significantly increased blastocyst formation rates and total cell numbers after parthenogenetic activation (30.3% and 63.9 vs. 21.6% and 36.5, respectively) and SCNT (18.2% and 53.7 vs. 12.6% and 37.5, respectively), when compared with the control group. Cumulus cells treated with 50 µM of lanosterol showed significantly increased 14α-demethylase, Δ14-reductase, and Δ7-reductase mRNA transcript levels. Significantly increased PPARγ, SREBF1, GPX1, and Bcl-2 and decreased Bax transcript levels were observed in mature oocytes treated with 50 µM of lanosterol compared with the control. SCNT blastocysts derived from 50-µM lanosterol-treated oocytes had significantly higher POU5F1, FGFR2, and Bcl-2 transcript levels than control SCNT-derived blastocysts. In conclusion, supplementation with 50 µM of lanosterol during IVM improves preimplantation development of SCNT embryos by elevating lipid content of oocytes, increasing GSH levels, decreasing reactive oxygen species levels, and regulating genes related to the cholesterol biosynthetic pathway in cumulus cells, to lipid metabolism and apoptosis in oocytes, and their developmental potential and apoptosis in blastocysts.


Asunto(s)
Clonación de Organismos/veterinaria , Citoplasma/efectos de los fármacos , Desarrollo Embrionario/efectos de los fármacos , Técnicas de Maduración In Vitro de los Oocitos/veterinaria , Lanosterol/farmacología , Porcinos/embriología , Animales , Blastocisto/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Lanosterol/administración & dosificación
9.
Neuroscience ; 303: 126-37, 2015 Sep 10.
Artículo en Inglés | MEDLINE | ID: mdl-26143011

RESUMEN

Evidences suggest protein kinase C epsilon (PKCε) activation is involved in both inflammatory and neuropathic pains. We have previously shown that tetracyclic triterpene euphol produces antinociception in different models of persistent pain, an action associated with its anti-inflammatory properties. Among these properties are the cannabinoid system activation and different PKC isozymes modulation. Herein, we sought to explore the potential role of PKCε modulation on euphol antinociceptive effect, in inflammatory and neuropathic pain models, in rodents. Also, we investigated further mechanisms associated with euphol effects. Oral treatment with euphol (30 mg/kg) prevented the putative effect of PGE2-induced acute and persistent mechanical hypersensitivity in mice and rats, respectively. In the PGE2-induced acute mechanical hypersensitivity euphol promoted an inhibitory effect similar to a PKCε inhibitor peptide. Likewise, in rats it prevented the mechanical hypersensitivity induced by a PKCε activator. Conversely, euphol effectiveness was not observed in a cAMP/PKA-induced mechanical hypersensitivity in mice. Single (1h prior) or repeated (twice daily during 3 or 13 days) treatments with euphol ameliorated painful peripheral neuropathy induced by paclitaxel and also the mechanical hypersensitivity induced by B16F10 melanoma cells injection, in mice. Additionally, in both inflammatory and neuropathic pain models, euphol consistently prevented PKCε up-regulation, as well as, inhibited the up-regulation of PKCε-activated intracellular pathways; namely nuclear factor-κB (NF-κB), cyclic AMP response element binding protein (CREB) and cyclo-oxygenase-2 (COX-2). The present results suggest the antinociceptive effect on persistent pain caused by euphol is likely dependent on the inhibition of pro-inflammatory mediators modulated by PKCε.


Asunto(s)
Analgésicos/administración & dosificación , Lanosterol/análogos & derivados , Dolor/metabolismo , Dolor/prevención & control , Proteína Quinasa C-epsilon/metabolismo , Animales , Antiinflamatorios/administración & dosificación , Dinoprostona/administración & dosificación , Mediadores de Inflamación/metabolismo , Lanosterol/administración & dosificación , Masculino , Ratones , Dolor/inducido químicamente , Umbral del Dolor/efectos de los fármacos , Proteína Quinasa C-epsilon/administración & dosificación , Ratas , Ratas Wistar , Transducción de Señal/efectos de los fármacos
10.
Nature ; 523(7562): 607-11, 2015 Jul 30.
Artículo en Inglés | MEDLINE | ID: mdl-26200341

RESUMEN

The human lens is comprised largely of crystallin proteins assembled into a highly ordered, interactive macro-structure essential for lens transparency and refractive index. Any disruption of intra- or inter-protein interactions will alter this delicate structure, exposing hydrophobic surfaces, with consequent protein aggregation and cataract formation. Cataracts are the most common cause of blindness worldwide, affecting tens of millions of people, and currently the only treatment is surgical removal of cataractous lenses. The precise mechanisms by which lens proteins both prevent aggregation and maintain lens transparency are largely unknown. Lanosterol is an amphipathic molecule enriched in the lens. It is synthesized by lanosterol synthase (LSS) in a key cyclization reaction of a cholesterol synthesis pathway. Here we identify two distinct homozygous LSS missense mutations (W581R and G588S) in two families with extensive congenital cataracts. Both of these mutations affect highly conserved amino acid residues and impair key catalytic functions of LSS. Engineered expression of wild-type, but not mutant, LSS prevents intracellular protein aggregation of various cataract-causing mutant crystallins. Treatment by lanosterol, but not cholesterol, significantly decreased preformed protein aggregates both in vitro and in cell-transfection experiments. We further show that lanosterol treatment could reduce cataract severity and increase transparency in dissected rabbit cataractous lenses in vitro and cataract severity in vivo in dogs. Our study identifies lanosterol as a key molecule in the prevention of lens protein aggregation and points to a novel strategy for cataract prevention and treatment.


Asunto(s)
Catarata/tratamiento farmacológico , Catarata/metabolismo , Lanosterol/farmacología , Lanosterol/uso terapéutico , Agregado de Proteínas/efectos de los fármacos , Agregación Patológica de Proteínas/tratamiento farmacológico , Adulto , Secuencia de Aminoácidos , Amiloide/química , Amiloide/efectos de los fármacos , Amiloide/metabolismo , Amiloide/ultraestructura , Animales , Secuencia de Bases , Catarata/congénito , Catarata/genética , Catarata/patología , Línea Celular , Niño , Cristalinas/química , Cristalinas/genética , Cristalinas/metabolismo , Cristalinas/ultraestructura , Perros , Femenino , Humanos , Lanosterol/administración & dosificación , Cristalino/efectos de los fármacos , Cristalino/metabolismo , Cristalino/patología , Masculino , Modelos Moleculares , Datos de Secuencia Molecular , Proteínas Mutantes/química , Proteínas Mutantes/genética , Proteínas Mutantes/metabolismo , Proteínas Mutantes/ultraestructura , Linaje , Agregación Patológica de Proteínas/patología
11.
Tumour Biol ; 36(9): 7027-34, 2015 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-25864108

RESUMEN

Recurrent meningiomas constitute an uncommon but significant problem after standard (surgery and radiation) therapy failure. Current chemotherapies (hydroxyurea, RU-486, and interferon-α) are only of marginal benefit. There is an urgent need for more effective treatments for meningioma patients who have failed surgery and radiation therapy. Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM are some of the plant derivatives that have anti-tumorgenic properties and cause cell death in meningioma cells in vitro. Due to its ease of administration, long-term tolerability, and low incidence of long-term side effects, we explored its potential as a therapeutic agent against meningiomas by examining their efficacy in vitro against meningioma cells. Treatment effects were assessed using MTT assay, Western blot analysis, caspases assay, and DNA fragmentation assay. Results indicated that treatments of IOMM-Lee and CH157MN meningioma cells with Limonin, Tangeritin, Zerumbone, 6-Gingerol, Ganoderic Acid A, and Ganoderic Acid DM induced apoptosis with enhanced phosphorylation of glycogen synthase kinase 3 ß (GSK3ß) via inhibition of the Wnt5/ß-catenin pathway. These drugs did not induce apoptosis in normal human neurons. Other events in apoptosis included downregulation of tetraspanin protein (TSPAN12), survival proteins (Bcl-XL and Mcl-1), and overexpression apoptotic factors (Bax and caspase-3). These results provide preliminary strong evidence that medicinal plants containing Limonin, Tangeritin, 6-Gingerol, Zerumbone, Ganoderic Acid A, and Ganoderic Acid DM can be applied to high-grade meningiomas as a therapeutic agent, and suggests that further in vivo studies are necessary to explore its potential as a therapeutic agent against malignant meningiomas.


Asunto(s)
Catecoles/administración & dosificación , Alcoholes Grasos/administración & dosificación , Flavonas/administración & dosificación , Ácidos Heptanoicos/administración & dosificación , Lanosterol/análogos & derivados , Limoninas/administración & dosificación , Meningioma/tratamiento farmacológico , Sesquiterpenos/administración & dosificación , Triterpenos/administración & dosificación , Apoptosis/efectos de los fármacos , Catecoles/química , Línea Celular Tumoral , Fragmentación del ADN/efectos de los fármacos , Alcoholes Grasos/química , Flavonas/química , Glucógeno Sintasa Quinasa 3/biosíntesis , Glucógeno Sintasa Quinasa 3/genética , Glucógeno Sintasa Quinasa 3 beta , Ácidos Heptanoicos/química , Humanos , Lanosterol/administración & dosificación , Lanosterol/química , Limoninas/química , Meningioma/genética , Meningioma/patología , Sesquiterpenos/química , Triterpenos/química , Vía de Señalización Wnt/efectos de los fármacos
12.
Food Chem ; 141(3): 3020-7, 2013 Dec 01.
Artículo en Inglés | MEDLINE | ID: mdl-23871054

RESUMEN

The hepatoprotective effects of eburicoic acid (TR1) and dehydroeburicoic acid (TR2) from Antrodia camphorata (AC) against carbon tetrachloride (CCl4)-induced liver damage were investigated in mice. TR1 and TR2 was administered intraperitoneally (i.p.) for 7 days prior to the administration of CCl4. Pretreatment with TR1 and TR2 prevented the elevation of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and liver lipid peroxides in CCl4-treated mice. The activities of antioxidant enzymes [catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx)], nitric oxide (NO) production, and tumour necrosis factor-alpha (TNF-α) were decreased after the treatment with TR1 and TR2 in CCl4-treated mice. Western blotting revealed that TR1 and TR2 significantly decreased inducible nitric oxide synthase (iNOS) and cyclooxygenase-2 (COX-2) expressions and increased the expression of cytochrome P4502E1 (CYP2E1) in CCl4-treated mice. Therefore, we speculate that TR1 and TR2 protect the liver from CCl4-induced hepatic damage via antioxidant and anti-inflammatory mechanisms.


Asunto(s)
Antrodia/química , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Lanosterol/análogos & derivados , Enfermedad Aguda/terapia , Alanina Transaminasa/genética , Alanina Transaminasa/metabolismo , Animales , Aspartato Aminotransferasas/genética , Aspartato Aminotransferasas/metabolismo , Tetracloruro de Carbono/efectos adversos , Enfermedad Hepática Inducida por Sustancias y Drogas/tratamiento farmacológico , Enfermedad Hepática Inducida por Sustancias y Drogas/enzimología , Enfermedad Hepática Inducida por Sustancias y Drogas/etiología , Modelos Animales de Enfermedad , Glutatión Peroxidasa/genética , Glutatión Peroxidasa/metabolismo , Humanos , Lanosterol/administración & dosificación , Hígado/efectos de los fármacos , Hígado/enzimología , Masculino , Ratones , Ratones Endogámicos ICR , Óxido Nítrico/metabolismo , Estrés Oxidativo/efectos de los fármacos , Superóxido Dismutasa/genética , Superóxido Dismutasa/metabolismo
13.
J Agric Food Chem ; 61(21): 5064-71, 2013 May 29.
Artículo en Inglés | MEDLINE | ID: mdl-23495748

RESUMEN

Eburicoic acid (TR1) and dehydroeburicoic acid (TR2), an active ingredient from Antrodia camphorata (AC) solid-state culture, were evaluated for analgesic and anti-inflammatory effects. Treatment with TR1 and TR2 significantly inhibited a number of acetic acid-induced writhing responses and formalin-induced pain in the late phase. In the anti-inflammatory test, TR1 and TR2 decreased paw edema at the fourth and fifth hour after λ-carrageenan (Carr) administration and increased the activities of catalase (CAT), superoxide dismutase (SOD), and glutathione peroxidase (GPx) in the paw edema tissue. We also demonstrated that TR1 and TR2 significantly attenuated the malondialdehyde (MDA), nitric oxide (NO), tumor necrosis factor (TNF-α), and interleukin-1ß (IL-1ß) levels in either edema paw or serum at the fifth hour after Carr injection. Western blotting revealed that TR1 and TR2 decreased Carr-induced inducible nitric oxide synthase (iNOS) and cycloxyclase (COX-2) expressions at the fifth hour in paw edema. Treatment with TR1 and TR2 also diminished neutrophil infiltration into the paw edema at the fifth hour. The present study suggests that the anti-inflammatory mechanisms of TR1 and TR2 might be related to the decrease of inflammatory cytokines and an increase of antioxidant enzyme activity.


Asunto(s)
Analgésicos/administración & dosificación , Antiinflamatorios/administración & dosificación , Antrodia/química , Edema/tratamiento farmacológico , Mediadores de Inflamación/inmunología , Lanosterol/análogos & derivados , Animales , Edema/genética , Edema/inmunología , Glutatión Peroxidasa/genética , Glutatión Peroxidasa/inmunología , Humanos , Interleucina-1beta/genética , Interleucina-1beta/inmunología , Lanosterol/administración & dosificación , Masculino , Ratones , Ratones Endogámicos ICR , Óxido Nítrico/inmunología , Óxido Nítrico Sintasa de Tipo II , Factor de Necrosis Tumoral alfa/genética , Factor de Necrosis Tumoral alfa/inmunología
14.
Eur J Pharmacol ; 698(1-3): 413-20, 2013 Jan 05.
Artículo en Inglés | MEDLINE | ID: mdl-23099255

RESUMEN

Inflammation underlies the development and progression of a number of skin disorders including psoriasis, atopic dermatitis and cancer. Therefore, novel antiinflammatory agents are of great clinical interest for prevention and treatment of these conditions. Herein, we demonstrated the underlying molecular mechanisms of the antiinflammatory activity of euphol, a tetracyclic triterpene isolated from the sap of Euphorbia tirucalli, in skin inflammation induced by 12-O-tetradecanoylphorbol-13-acetate (TPA) in mice. Topical application of euphol (100 µg/ear) significantly inhibited TPA-induced ear edema and leukocyte influx through the reduction of keratinocyte-derived chemokine (CXCL1/KC) and macrophage inflammatory protein (MIP)-2 levels. At the intracellular level, euphol reduced TPA-induced extracellular signal-regulated protein kinase (ERK) activation and cyclooxygenase-2 (COX-2) upregulation. These effects were associated with euphol's ability to prevent TPA-induced protein kinase C (PKC) activation, namely PKCα and PKCδ isozymes. Our data indicate that topical application of euphol markedly inhibits the inflammatory response induced by TPA. Thus, euphol represents a promising agent for the management of skin diseases with an inflammatory component.


Asunto(s)
Quinasas MAP Reguladas por Señal Extracelular/metabolismo , Lanosterol/análogos & derivados , Sistema de Señalización de MAP Quinasas/efectos de los fármacos , Proteína Quinasa C/metabolismo , Enfermedades de la Piel/inducido químicamente , Enfermedades de la Piel/tratamiento farmacológico , Acetato de Tetradecanoilforbol/efectos adversos , Administración Tópica , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/farmacología , Antiinflamatorios no Esteroideos/uso terapéutico , Ciclooxigenasa 2/metabolismo , Edema/inducido químicamente , Edema/tratamiento farmacológico , Edema/inmunología , Edema/patología , Activación Enzimática/efectos de los fármacos , Inflamación/inducido químicamente , Inflamación/tratamiento farmacológico , Inflamación/inmunología , Inflamación/patología , Lanosterol/administración & dosificación , Lanosterol/farmacología , Lanosterol/uso terapéutico , Leucocitos/efectos de los fármacos , Leucocitos/inmunología , Masculino , Ratones , Proteína Quinasa 1 Activada por Mitógenos/metabolismo , Proteína Quinasa 3 Activada por Mitógenos/metabolismo , Enfermedades de la Piel/inmunología , Enfermedades de la Piel/patología , Regulación hacia Arriba/efectos de los fármacos
15.
Neuropharmacology ; 63(4): 593-605, 2012 Sep.
Artículo en Inglés | MEDLINE | ID: mdl-22613837

RESUMEN

Persistent pains associated with inflammatory and neuropathic states are prevalent and debilitating diseases, which still remain without a safe and adequate treatment. Euphol, an alcohol tetracyclic triterpene, has a wide range of pharmacological properties and is considered to have anti-inflammatory action. Here, we assessed the effects and the underlying mechanisms of action of euphol in preventing inflammatory and neuropathic pain. Oral treatment with euphol (30 and 100 mg/kg) reduced carrageenan-induced mechanical hyperalgesia. Likewise, euphol given through the spinal and intracerebroventricular routes prevented mechanical hyperalgesia induced by carrageenan. Euphol consistently blocked the mechanical hyperalgesia induced by complete Freund's adjuvant, keratinocyte-derived chemokine, interleukin-1ß, interleukin-6 and tumor necrosis factor-alpha associated with the suppression of myeloperoxidase activity in the mouse paw. Oral treatment with euphol was also effective in preventing the mechanical nociceptive response induced by ligation of the sciatic nerve and also significantly reduced the levels and mRNA of cytokines/chemokines in both paw and spinal cord tissues following i.pl. injection of complete Freund's adjuvant. In addition, the pre-treatment with either CB1R or CB2R antagonists, as well as the knockdown gene of the CB1R and CB2R, significantly reversed the antinociceptive effect of euphol. Interestingly, even in higher doses, euphol did not cause any relevant action in the central nervous system. Considering that few drugs are currently available for the treatment of chronic pain states, the present results provided evidence that euphol constitutes a promising molecule for the management of inflammatory and neuropathic pain states.


Asunto(s)
Antiinflamatorios no Esteroideos/uso terapéutico , Edema/prevención & control , Hiperalgesia/prevención & control , Lanosterol/análogos & derivados , Neuralgia/prevención & control , Receptor Cannabinoide CB1/metabolismo , Receptor Cannabinoide CB2/metabolismo , Animales , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/antagonistas & inhibidores , Antiinflamatorios no Esteroideos/farmacología , Conducta Animal/efectos de los fármacos , Citocinas/genética , Citocinas/metabolismo , Relación Dosis-Respuesta a Droga , Regulación hacia Abajo/efectos de los fármacos , Edema/inmunología , Edema/metabolismo , Técnicas de Silenciamiento del Gen , Miembro Posterior/efectos de los fármacos , Miembro Posterior/metabolismo , Hiperalgesia/inmunología , Hiperalgesia/metabolismo , Lanosterol/administración & dosificación , Lanosterol/antagonistas & inhibidores , Lanosterol/farmacología , Lanosterol/uso terapéutico , Masculino , Ratones , Neuralgia/inmunología , Neuralgia/metabolismo , Infiltración Neutrófila/efectos de los fármacos , Dimensión del Dolor , ARN Mensajero/metabolismo , Receptor Cannabinoide CB1/antagonistas & inhibidores , Receptor Cannabinoide CB1/genética , Receptor Cannabinoide CB2/antagonistas & inhibidores , Receptor Cannabinoide CB2/genética , Médula Espinal/efectos de los fármacos , Médula Espinal/metabolismo
16.
Eur J Pharmacol ; 681(1-3): 23-33, 2012 Apr 15.
Artículo en Inglés | MEDLINE | ID: mdl-22366428

RESUMEN

Ganoderic acid T, a triterpenic acid produced by Ganoderma lucidum, has demonstrated therapeutic potential for tumor disease. In the current work, ganoderic acid T was modified to produce more effective small-molecule inhibitors of cancer cell proliferation. Moreover, the anticancer effects of three new ganoderic acid T derivatives, i.e., (22S,24E)-3α,15α,22-triacetoxy-5α-lanosta-7,9(11),24-trien-26-oic acid ethyl ester (TLTO-Ee), (22S,24E)-3α,15α,22-triacetoxy-5α-lanosta-7,9(11),24-trien-26-oic acid propyl ester (TLTO-Pe), and (22S,24E)-3α,15α,22-triacetoxy-5α-lanosta-7,9(11),24-trien-26-oic acid amide (TLTO-A), and one known derivative, (22S,24E)-3α,15α,22-triacetoxy-5α-lanosta-7,9(11),24-trien-26-oic acid methyl ester (TLTO-Me), on the cervical cell line HeLa were investigated and compared. MTT assay indicated that, among the tested compounds, TLTO-A displayed the highest inhibitory effect on the growth of HeLa cells, whereas it showed less cytotoxicity to the non-tumorous cell line MCF-10A than ganoderic acid T. Flow cytometry analysis revealed that all the compounds caused cell cycle arrest at the G1 phase and induced apoptosis. Furthermore, they decreased the mitochondrial membrane potential and enhanced the activities of pro-apoptotic factors caspase-3 and caspase-9 in a dose-dependent manner. Accordingly, the apoptosis induction was presumed to occur through the endogenous pathway. The following order ranks both cytotoxic and pro-apoptotic effects of the compounds against HeLa cells: TLTO-A>ganoderic acid T≈TLTO-Me≈TLTO-Ee≈TLTO-Pe. This study suggests that the carboxyl group of ganoderic acid T is not the main active group and is suitable for its further structural modification. The current work presents valuable information on the design of ganoderic acid T derivatives to develop potential chemotherapy agents.


Asunto(s)
Antineoplásicos/farmacología , Apoptosis/efectos de los fármacos , Lanosterol/análogos & derivados , Neoplasias del Cuello Uterino/tratamiento farmacológico , Antineoplásicos/administración & dosificación , Antineoplásicos/química , Caspasa 3/metabolismo , Caspasa 9/metabolismo , Línea Celular , Proliferación Celular/efectos de los fármacos , Relación Dosis-Respuesta a Droga , Femenino , Citometría de Flujo , Puntos de Control de la Fase G1 del Ciclo Celular/efectos de los fármacos , Células HeLa , Humanos , Lanosterol/administración & dosificación , Lanosterol/química , Lanosterol/farmacología , Potencial de la Membrana Mitocondrial/efectos de los fármacos , Neoplasias del Cuello Uterino/patología
17.
Res Commun Mol Pathol Pharmacol ; 103(1): 91-100, 1999 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-10440574

RESUMEN

Dihydrolanosterol (DHL) and its analogs have been studied extensively as cholesterol biosynthesis inhibitors. They inhibit specific steps in cholesterol synthesis by inhibiting lanosterol demethylase and by suppressing HMG-CoA reductase. The present study was designed to estimate the lymphatic absorption of DHL. For comparison, a cholesterol group was included. The left thoracic duct of male Wistar rats weighing between 210 and 230 g was cannulated. A lipid emulsion containing 0.75microCi of either [3H]-DHL or [3H]-cholesterol was given intragastrically. After the lipid meal, lymph was collected at 3 h intervals up to 9 h and then at 24 h. Radioactivity of DHL and cholesterol in the lymph was estimated. Lipid extracts of lymph specimens were also subjected to thin layer chromatography and fractions of DHL, cholesterol and their esters were isolated and the masses were estimated. There were no differences in lymph volumes between the two groups. However, absorption and esterification of DHL in lymph were significantly reduced compared with the cholesterol group. The marked decrease in the esterification of DHL is likely due to its poor absorption into the mucosal cell and subsequently into the lymphatic system. The amount of DHL available in the mucosal cell for esterification may be a limiting factor.


Asunto(s)
Colesterol/metabolismo , Lanosterol/análogos & derivados , Sistema Linfático/metabolismo , Animales , Peso Corporal , Colesterol/administración & dosificación , Esterificación , Lanosterol/administración & dosificación , Lanosterol/metabolismo , Linfa , Sistema Linfático/fisiología , Masculino , Ratas , Ratas Wistar
18.
Physiol Chem Phys ; 13(4): 348-51, 1981.
Artículo en Inglés | MEDLINE | ID: mdl-7330098

RESUMEN

Lanosterol, a precursor of cholesterol, is ingested with human diet and occurs in the body in concentrations exceeding solubility. Flesh of immature animals is a common source of dietary lanosterol, which may form with cholestanol and water an insoluble adjunct, CL-2W. As the latter may contribute to various disorders, exogenous lanosterol should be avoided by diet adjustment.


Asunto(s)
Lanosterol/metabolismo , Animales , Encéfalo/metabolismo , Colestanoles/metabolismo , Colesterol/biosíntesis , Cosméticos , Dieta , Humanos , Lanosterol/administración & dosificación , Lanosterol/efectos adversos , Verduras/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...